Amgen Epogen Profit Margins Could Rise 1% After Columbia Patent Expires
Executive Summary
Amgen could see its profit margins on Epogen increase by 1% in August if Columbia University fails to obtain a five-year extension on a biotechnology process patent.
You may also be interested in...
NIH Return-On-Investment Report Will Be Subject Of Senate Hearing This Fall
The Senate Commerce/Science Subcommittee will hold hearings this fall on the return to taxpayers from research funded by the National Institutes of Health.
NIH Return-On-Investment Report Will Be Subject Of Senate Hearing This Fall
The Senate Commerce/Science Subcommittee will hold hearings this fall on the return to taxpayers from research funded by the National Institutes of Health.
Patent extensions
Supplemental appropriations bill is being eyed as vehicle for legislative proposals that could alternatively improve and hamper brand-name pharmaceutical industry profitability. A measure to provide patent restoration for "pipeline" drugs - notably Schering's Claritin - has been expanded to include animal drugs, food additives and medical devices. Sen. Gregg (R-N.H.) is seeking an extension for a Columbia University patent on which many biotech companies pay royalties (1"The Pink Sheet" May 22, p. 27). A vote on the bill is expected the week of June 26